Susan Swindells

1993–2024 年に発表

83
論文数
21,551
被引用数
51
h 指数
79
i10 指数

被引用数

Susan Swindells の年別被引用数1977 年: 被引用 1 件1989 年: 被引用 1 件1994 年: 被引用 2 件1995 年: 被引用 12 件1996 年: 被引用 17 件1997 年: 被引用 23 件1998 年: 被引用 32 件1999 年: 被引用 30 件2000 年: 被引用 25 件2001 年: 被引用 60 件2002 年: 被引用 100 件2003 年: 被引用 106 件2004 年: 被引用 82 件2005 年: 被引用 79 件2006 年: 被引用 101 件2007 年: 被引用 77 件2008 年: 被引用 108 件2009 年: 被引用 90 件2010 年: 被引用 82 件2011 年: 被引用 112 件2012 年: 被引用 182 件2013 年: 被引用 181 件2014 年: 被引用 185 件2015 年: 被引用 146 件2016 年: 被引用 141 件2017 年: 被引用 103 件2018 年: 被引用 114 件2019 年: 被引用 551 件2020 年: 被引用 523 件2021 年: 被引用 551 件2022 年: 被引用 426 件2023 年: 被引用 281 件2024 年: 被引用 527 件2025 年: 被引用 180 件2026 年: 被引用 9 件1978〜1988 年は被引用が無いため表示していません1990〜1993 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,897 件、この内訳の 33.8%イギリス: 引用元論文 693 件、この内訳の 8.1%南アフリカ: 引用元論文 547 件、この内訳の 6.4%カナダ: 引用元論文 360 件、この内訳の 4.2%スイス: 引用元論文 254 件、この内訳の 3%フランス: 引用元論文 245 件、この内訳の 2.9%イタリア: 引用元論文 203 件、この内訳の 2.4%オーストラリア: 引用元論文 202 件、この内訳の 2.3%ドイツ: 引用元論文 195 件、この内訳の 2.3%スペイン: 引用元論文 193 件、この内訳の 2.2%オランダ: 引用元論文 189 件、この内訳の 2.2%ウガンダ: 引用元論文 188 件、この内訳の 2.2%
0%33.8%その他 28%

分野

  • Medicine76.3%
  • Immunology and Microbiology12.1%
  • Biochemistry, Genetics and Molecular Biology3.2%
  • Neuroscience2.6%
  • Health Professions1.9%
  • Social Sciences1%
  • その他2.9%

トピック

  • HIV/AIDS Research and Interventions20.2%
  • HIV Research and Treatment12%
  • HIV/AIDS drug development and treatment10.2%
  • HIV-related health complications and treatments6.4%
  • HIV, Drug Use, Sexual Risk6.2%
  • Adolescent Sexual and Reproductive Health3.8%
  • その他41.2%

共著者

全論文

検索で開く
  1. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 565

  2. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard E. Chaisson - New England Journal of Medicine 2021 被引用: 551

  3. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2020 被引用: 364

  4. Prevention of HIV-1 Infection with Early Antiretroviral Therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Taha E. Taha, Karin Nielsen‐Saines, David D. Celentano, Max Essex, Thomas R. Fleming - New England Journal of Medicine 2011 被引用: 6,962

  5. Antiretroviral Therapy for the Prevention of HIV-1 Transmission

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karin Nielsen‐Saines, David D. Celentano, Max Essex, Sarah E. Hudelson, Andrew D. Redd, Thomas R. Fleming - New England Journal of Medicine 2016 被引用: 1,726

  6. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2023 被引用: 124

  7. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection

    著者: , , , , , , , - Annals of Internal Medicine 2000 被引用: 3,328

  8. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 370

  9. Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLA

    著者: , , , , , , , , , , , , , , - Molecular Cell 2016 被引用: 320

  10. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

    著者: , , , , , , , , , , , , - Patient 2021 被引用: 78

  11. Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial

    著者: , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2020 被引用: 68

  12. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.

    著者: , , , , , , , , , , , , , , , , , , , , - AIDS 2021 被引用: 97

  13. Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Faiz Ahmad Khan, Andrea A Howard, Robin Wood, Swe Swe Thit, Mar Mar Kyi, Josh Hanson, Paul K Drain, Adrienne E Shapiro, Tendesayi Kufa, Gavin Churchyard, Duc T Nguyen, Edward A Graviss, Stephanie Bjerrum, Isik S Johansen, Jill K Gersh, David J Horne, Sylvia M LaCourse, Haider Abdulrazzaq Abed Al-Darraji, Adeeba Kamarulzaman, Russell R Kempker, Nestani Tukvadze, David A Barr, Graeme Meintjes, Gary Maartens - The Lancet Infectious Diseases 2021 被引用: 70

  14. The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?

    著者: , - Journal of the International Association of Providers of AIDS Care (JIAPAC) 2021 被引用: 95

  15. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Simon Vanveggel, Rodica Van Solingen‐Ristea, Herta Crauwels, Kimberly Y. Smith, William Spreen, David A. Margolis - JAIDS Journal of Acquired Immune Deficiency Syndromes 2020 被引用: 149

  16. Long-acting drugs and formulations for the treatment and prevention of HIV infection

    著者: , , , - International Journal of Antimicrobial Agents 2020 被引用: 105

  17. Aberrant occipital dynamics differentiate HIV-infected patients with and without cognitive impairment

    著者: , , , , , , - Brain 2018 被引用: 91

  18. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Max Essex, Diane V. Havlir, Myron S. Cohen - The Lancet Infectious Diseases 2014 被引用: 511

  19. Interest of Youth Living With HIV in Long-Acting Antiretrovirals

    著者: , , , , , , , , , - JAIDS Journal of Acquired Immune Deficiency Syndromes 2018 被引用: 78

  20. Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection

    著者: , , , , - AIDS Care 2020 被引用: 73

  21. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Issa Sabi, Modulakgotla Sebe, Raesibe AP Selepe, Suzanne Staples, Susan Swindells, C.H. van Niekerk, Ebrahim Variava, Melvin Spigelman, Stephen H. Gillespie - The International Journal of Tuberculosis and Lung Disease 2021 被引用: 63

  22. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

    著者: , , , , , , , , , , , , , , , - BMC Health Services Research 2021 被引用: 53

  23. A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial

    著者: , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2021 被引用: 29

  24. Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States

    著者: , , , , , - Open Forum Infectious Diseases 2019 被引用: 102